Randomized trial examines the effect of risankizumab on ulcerative colitis in patients unresponsive to ustekinumab, suggesting potential benefits.
Key Points
The aim is to evaluate the effectiveness of risankizumab as an induction therapy for patients with ulcerative colitis who did not respond to ustekinumab.
Analysis of real-world data on risankizumab use in patients with ustekinumab-refractory ulcerative colitis.
Assessment of C-reactive protein levels as an inflammation marker.
C-reactive protein levels were measured with a median of 0.04 mg/dL (range 0.03-2.50) after treatment, indicating a reduction in inflammation.
Another cohort showed median C-reactive protein of 0.21 mg/dL (range 0.07-2.03), suggesting variable responses to treatment.